- €2.20bn
- €2.16bn
- €1.11bn
Brief: Almirall 9M Sales EUR 727.6 Million
Brief: Almirall Completes Decentralized Regulatory Approval Procedure For Efinaconazole In Europe
Brief: Ebglyss Provided Sustained Disease Control For Up To 3 Years In Over 80% Of Adults And Adolescents With Atopic Dermatitis - Almirall
Almirall jumps after H1 profit beat
Spanish stocks - Factors to watch on July 22
Brief: Almirall H1 Net Profit Up At 15.4 Mln Euros YoY
Brief: Almirall Reiterates 2024 Guidance
Brief: Almirall's Ilumetri Improves Psorasis Patients' Wellbeing For Up To 1 Year
Brief: Almirall Says FDA Approves Klisyri For Actinic Keratosis Treatment On Expanded Areas
Brief: Almirall Gives Information On Dividend
Europe Research Roundup: Alfa Laval, OMV AG, Unilever Plc
Almirall shares rise after net profit falls less than forecast (updated)
Almirall jumps after Q1 beat, guidance confirmation
Spanish stocks - Factors to watch on May 13
Almirall confirms full-year target despite higher costs in first quarter
Brief: Almirall Approves Payment Of Dividend Of 39.8 Mln Euros
Brief: Almirall Q1 EBITDA EUR 52.5 Million
Brief: Almirall Says It's On Target To Meet 2024 Guidance
Brief: Almirall Proposes Share Capital Increase Through Issue Of New Ordinary Shares Of 0.12 Euros Par Value Each, With No Share Premium